New filler JTM102 takes on juvederm in Face-Off trial
NCT ID NCT07265778
First seen Jun 26, 2026 · Last updated Jul 24, 2026 · Updated 2 times
Summary
This study tests a new hyaluronic acid filler called JTM102 against the well-known Juvederm VOLUMA for restoring volume in the mid-face area. About 149 adults aged 19 to 65 with mid-face volume loss will receive both fillers on different sides of their face to compare results. The goal is to see if JTM102 is as safe and effective for temporary correction.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- hyaluronic acid filler with lidocaine
- What this could lead to
- If JTM102 works as well as Juvederm, it could offer another safe option for temporarily restoring mid-face volume.
- What could go wrong
- This is a pivotal study but still early for this specific filler. Results may not show a clear advantage, and individual results vary. Risks include typical filler side effects like swelling or bruising.
Why investors are watching
Jetema is testing JTM102, an injectable filler, against Juvederm Voluma in a 149-patient study for mid-face volume loss. For a small company, a successful head-to-head result against an established product could validate JTM102 as a viable competitor and support its commercial prospects.
If it works: A positive result could position JTM102 as a credible alternative to a leading filler, potentially opening a path to market entry and revenue generation for Jetema.
If it fails: The trial could fail to show JTM102 matches Juvederm's safety or effectiveness, or the study could face delays. Clinical trials often fail, and a negative outcome would likely hurt Jetema's prospects.
AI-written from the trial record. Speculative, and not investment advice.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 149 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Oct 2024
- Expected to finish
-
Feb 2027
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
19 to 65 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Subjects who voluntarily agree to participate in this clinical trial. * Adults aged 19 to 65 years. * Subjects who desire temporary improvement of mid-face volume and whose Mid-face volume deficit level meets eligibility criteria * Subjects who agree to discontinue all dermatological treatments or procedures for the face during the clinical trial period, including wrinkle improvement treatments such as fillers, botulinum toxin, laser therapy, chemical peels, and cosmetic surgeries, except for the investigational medical device application. * Subjects who use medically acceptable contraception methods throughout the clinical trial period (pregnant or breastfeeding women are excluded). * Subjects who understand and can comply with the study instructions and can participate for the entire duration of the clinical trial. Exclusion Criteria: * History or concurrent conditions included in exclusion criteria * History of procedures (including surgery) included in exclusion criteria * Use of medications that may affect evaluation of the investigational device: * Any other conditions judged by the investigator as inappropriate for participation in this clinical trial.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Mid face volume deficit are added.
Genom att skicka in godkänner du våra Användarvillkor
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Chungang University Hospital
Seoul, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.